<p>Kymera Therapeutics Inc. has announced the initiation of dosing in its BREADTH Phase 2b clinical trial evaluating KT-621, a first-in-class oral STAT6 degrader, in patients with moderate to severe eosinophilic asthma. The company expects to report data from the BREADTH trial in late 2027. Additionally, data from the ongoing BROADEN2 Phase 2b trial of KT-621 in moderate to severe atopic dermatitis is anticipated by mid-2027. The results from these studies have not yet been presented and are expected in the future. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9644716-en) on January 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

ARKG

Reuters

iShares Biotechnology ETF

Ark Genomic Revolution ETF

VanEck Biotech ETF

SPDR S&P Biotech

VG Health

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Kymera Therapeutics

Health Care Select Sector SPDR

iShares Global Healthcare

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Kymera Therapeutics Doses First Patient in Phase 2b Asthma Trial of KT-621